BridgeBio Pharma

PriceBridgeBio Pharma

BBIO

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Historical stock price chart and annual return over the past years

83%

5 years

% Total

BBIO
13%

5 years

Annual Return

BBIO